Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Gouda, Mohamed A. http://orcid.org/0000-0003-4829-6739
Iorgulescu, J. Bryan
Dadu, Ramona
Patel, Keyur
Sherman, Steven
Cabanillas, Maria http://orcid.org/0000-0002-5124-1811
Hu, Mimi
Castellanos, Luz E.
Amini, Behrang http://orcid.org/0000-0002-4962-3466
Meric-Bernstam, Funda http://orcid.org/0000-0001-6816-6072
Shen, Tao
Article History
Received: 13 October 2023
Accepted: 23 February 2024
First Online: 4 March 2024
Competing interests
: V.S. is on the advisory board of Illumina, Labcorp, Relay Therapeutics, Bayer, Jazz Pharmaceuticals, Regeneron, and Aadi Biosciences. V.S. reports research funding/grant support (to institution) for conducting clinical trials from AbbVie, Agensys, Inc., Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc., Boston Pharmaceuticals, D3 Bio, Inc., Dragonfly Therapeutics, Inc., Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc., Incyte Corporation, Inhibrx, Loxo Oncology, MedImmune, MultiVir, Inc., NanoCarrier, Co., National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda, Turning Point Therapeutics, and Vegenics Pty Ltd.; travel support from Helsinn Healthcare, Incyte Corporation, Novartis, and PharmaMar; consultancy/advisory board participation for Helsinn Healthcare, Jazz Pharmaceuticals, Incyte Corporation, Loxo Oncology/Eli Lilly, MedImmune, Novartis, QED Therapeutics, Relay Therapeutics, Daiichi-Sankyo, and R-Pharm US, Illumina, Bayer and other relationship with Medscape, OncLive (Educational CME). Scientific Advisory board participation (funding to institution) Relay therapeutics, Pheon therapeutics, Incyte, Novartis, Eli Lilly/ Loxo Oncology, Roche, Pfizer, Bayer, ABBVIE, Regeneron. Other: Clinical Care Communications, PERS (CME fees for education). R.D. reports research support from Eisai, Merck, Exelixis, and AstraZeneca; and advisory committee for Exelixis and Bayer. S.S. reports consulting for Lilly. M.H. reports research funding from Eli Lilly & Co (provided to the institution), steering committee for Eli Lilly & Co (no funding support). F.M.-B. reports consulting for AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd., Calibr (a division of Scripps Research), DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., GT Apeiron, Genentech Inc., Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd, Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks; advisory Committee membership for Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals, Theratechnologies, Zentalis; Sponsored Research (to the institution) from Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co.; other (travel related) from European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), Cholangiocarcinoma Foundation. The other authors declare no competing interests.